AUTHORS
Qing Zhang, MD, Xiaoqiang Zhao, N/A2, Yifei Chen, MD3, chao Li, N/A4, Zhengrong Liu5, Ping Wang6, tao Liu7, Qianying Pan, MD8, Xingchen Liu, MD9, Hao Guo, MD, PhD10, Xueli Jiao, MD11, Fenghua Gao12, Jingyi Yang, MD13, Haiping Yang, MD14, Jinxiao Yao15, Xiaojuan Liu16, Zhihui Li, MD17, Genjie Wang, N/A18, shuhao mei19, Ruijie Li20, Ning Hu21, Hongyan Ma22, Ran Zhao, MD23, Xiaoyan Lin24, Yanrong Shi25, Jianwei Du26, Jianling Chen27, Qiuhong Wang28, Cailing Wang29, Lihua Dong30, Zhihua Yao31, Fuli Qin32, Wenyong Li33, Xu Li34, Yuxiu Xu35, quande Lin, PhD36, Xiaojuan Zhang37, Guangli Luo38, Shen He39, Hongfei Lu40, Shuli Guo41, Keshu Zhou, PhD42
AFFILIATIONS
1 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
3 Jiangdu People's Hospital Affiliated to Yangzhou University, Yangzhou, China
4 Nanyang Central Hospital, Nanyang, China
5 Anyang People's Hospital, Anyang, China
6 Zhumadian Central Hospital, Zhumadian, China
7 Zhoukou Central Hospital, Zhoukou, China
8 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
9 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
10 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
11 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
12 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
13 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
14 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
15 The Second People's Hospital of Nanyang, Nanyang, China
16 The Second People's Hospital of Jiaozuo, Jiaozuo, China
17 Xinxiang Central Hospital,, Xinxiang, China
18 The First People's Hospital of Shangqiu, Shangqiu, China
19 Xuchang Central Hospital, Xuchang, China
20 Henan Provincial Chest Hospital, Zhengzhou, China
21 HuaiHe Hospital of Henan University, Kaifeng, China
22 The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
23 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
24 Puyang Oilfield General Hospital, Puyang, China
25 Pingmei Shenma Medical Group General Hospital, Pingdingshan, China
26 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
27 Pingdingshan Second People's Hospital, Pingdingshan, China
28 Jiyuan People's Hospital, Jiyuan, China
29 Anyang Cancer Hospital, Anyang, China
30 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
31 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
32 Zhengzhou Central Hospital, Zhengzhou, China
33 Jiaozuo People's Hospital, Jiaozuo, China
34 The First Affiliated Hospital of Henan University, Kaifeng, China
35 The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
36 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
37 The Fifth Clinical Medical College of Henan University of Chinese Medicine ( Zhengzhou People's Hospital ), ??, China
38 Luohe Central Hospital, Luohe, China
39 Kaifeng Central Hospital, Kaifeng, China
40 Huanghe Sanmenxia Hospital, Sanmenxia, China
41 Luoyang Central Hospital, Luoyang, China
42 the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
ABSTRACT
Background
Polatuzumab vedotin (pola), a CD79b-directed antibody-drug conjugate, has demonstrated efficacy in first-line (1L) and relapsed/refractory (R/R) DLBCL combination regimens (POLARIX, POLARGO). Real-world data from Chinese patients—who differ in molecular epidemiology (MCD/A53 enrichment) and access patterns—remain limited. We report a large multicenter cohort led by a provincial cancer center, characterizing real-world effectiveness, treatment delivery patterns, and molecular features of pola-based therapy.
Methods
We assembled 730 DLBCL patients treated with pola-based regimens (cutoff 2026-06-30) across a provincial cancer center (n=469) and prefectural hospitals (n=261); 550 were enrolled prospectively and 180 retrospectively. Baseline features, treatment backbone, best response (ORR/CR by investigator assessment), PFS, OS, and NGS/LymphGen classification were collected via a harmonized master database. Descriptive statistics summarized the cohort and prespecified subgroups (1L vs R/R; central vs prefectural); survival was estimated using Kaplan-Meier methods, and median follow-up was calculated using the reverse Kaplan-Meier method.
Results
Denominators vary by variable (non-missing data). Median age 65 years (IQR 55-74); male 337/701 (48%). IPI 3-5 360/622 (58%); stage III-IV 498/639 (78%). Of 532 response-evaluable patients (198 recently enrolled or on ongoing treatment at cutoff, not lost to follow-up): ORR 90.6%, CR 61.1%. At median follow-up 10.8 months (IQR 6.1-16.1), 12-month PFS 83%, 12-month OS 95%; median PFS and OS were not reached at data cutoff, with 95 PFS events and 31 OS events observed.
First-line (n=602): median age 65 (IQR 56-74); IPI 3-5 58%. Among 447 evaluable, ORR 95.7%, CR 65.1%; at median follow-up 10.3 months (IQR 5.7-15.2), 12-month PFS 88%, 12-month OS 96% (median not reached; not reported given limited follow-up). The reported CR (65.1%) includes patients assessed mid-treatment. Descriptively, CR was 79.2% (145/183) in those completing >=6 cycles versus 45.2% (52/115) in <6 cycles; this should not be read as a treatment effect of completion, since restricting to completers introduces immortal-time bias. The all-evaluable CR (65.1%) is the reported 1L estimate.
R/R (n=128): median age 64; IPI 3–5 in 59%. Among 85 evaluable, ORR was 63.5% and CR 40.0%; at a median follow-up of 13.2 months (IQR 8.0–19.9), 12-month PFS was 65% and 12-month OS 91% (median not reached; not reported given limited follow-up).
Care setting: Prefectural patients were older (median 70 vs 63 years) and higher-risk (IPI 3-5 68% vs 54%) than central-center patients, with variation in response assessment practices (ORR 98.4%/CR 57.2% vs central ORR 86.4%/CR 63.2%). These differences highlight the complexity of real-world oncology practice across healthcare settings.
Molecular landscape: NGS was available in 195/730 (27%). LymphGen distribution showed enrichment of MCD and A53 subtypes (NOS 57, MCD 31, A53 32, BN2 13, ST2 12, EZB 10, N1 5, unclassified 35), consistent with molecular patterns previously reported in Chinese DLBCL cohorts.
Conclusions
In this large real-world Chinese cohort, pola-based therapy achieved high response rates in a high-risk population (58% IPI 3–5), with 1L ORR 95.7%/CR 65.1% and encouraging early survival (12-month OS 95%). Favorable outcomes were observed among older, higher-risk prefectural patients (IPI 3–5 68%), and inclusion of both care levels captures the complexity of real-world oncology practice often absent from single-center series. The molecular landscape suggested enrichment of MCD/A53 subtypes reported in Chinese DLBCL cohorts. These data provide real-world evidence supporting pola-based regimens and establish a foundation for subgroup, MAIC, and molecular analyses in companion abstracts.
DISCLOSURES
Qing Zhang, MD: No relevant conflicts of interest to declare.